A detailed history of Acadian Asset Management LLC transactions in Ideaya Biosciences, Inc. stock. As of the latest transaction made, Acadian Asset Management LLC holds 4,405 shares of IDYA stock, worth $112,812. This represents 0.0% of its overall portfolio holdings.

Number of Shares
4,405
Holding current value
$112,812
% of portfolio
0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$30.37 - $43.05 $133,779 - $189,635
4,405 New
4,405 $139,000
Q2 2023

Aug 07, 2023

SELL
$13.33 - $25.53 $113,811 - $217,975
-8,538 Reduced 78.72%
2,308 $54,000
Q1 2023

May 11, 2023

SELL
$13.49 - $18.72 $197,196 - $273,648
-14,618 Reduced 57.41%
10,846 $148,000
Q4 2022

Feb 14, 2023

BUY
$14.47 - $18.17 $368,464 - $462,680
25,464 New
25,464 $461,000
Q2 2022

Aug 09, 2022

SELL
$8.28 - $13.88 $330,694 - $554,353
-39,939 Closed
0 $0
Q1 2022

May 12, 2022

SELL
$11.18 - $24.02 $2.33 Million - $5.01 Million
-208,692 Reduced 83.94%
39,939 $445,000
Q4 2021

Feb 10, 2022

SELL
$20.95 - $26.88 $1.9 Million - $2.43 Million
-90,549 Reduced 26.7%
248,631 $5.88 Million
Q3 2021

Nov 12, 2021

BUY
$17.26 - $27.08 $214,800 - $337,010
12,445 Added 3.81%
339,180 $8.64 Million
Q2 2021

Aug 11, 2021

BUY
$17.76 - $24.83 $2.08 Million - $2.91 Million
117,380 Added 56.07%
326,735 $6.86 Million
Q1 2021

May 11, 2021

BUY
$13.48 - $23.77 $1.42 Million - $2.51 Million
105,470 Added 101.53%
209,355 $4.92 Million
Q4 2020

Feb 11, 2021

BUY
$12.17 - $17.52 $995,615 - $1.43 Million
81,809 Added 370.58%
103,885 $1.45 Million
Q3 2020

Nov 09, 2020

BUY
$11.22 - $14.46 $247,692 - $319,218
22,076 New
22,076 $276,000

Others Institutions Holding IDYA

About IDEAYA Biosciences, Inc.


  • Ticker IDYA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 48,067,700
  • Market Cap $1.23B
  • Description
  • IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's lead product candidates include IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase I clinica...
More about IDYA
Track This Portfolio

Track Acadian Asset Management LLC Portfolio

Follow Acadian Asset Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Acadian Asset Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Acadian Asset Management LLC with notifications on news.